APA   Click to copy
Cerro-Herreros, E., González-Martínez, I., Moreno, N., Espinosa-Espinosa, J., Fernández-Costa, J. M., Colom-Rodrigo, A., … Artero, R. (2021). Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy. Molecular Therapy - Nucleic Acids, 26, 174–191. https://doi.org/10.1016/j.omtn.2021.07.017

Chicago/Turabian   Click to copy
Cerro-Herreros, E., I. González-Martínez, N. Moreno, J. Espinosa-Espinosa, J.M. Fernández-Costa, A. Colom-Rodrigo, S.J. Overby, et al. “Preclinical Characterization of AntagomiR-218 as a Potential Treatment for Myotonic Dystrophy.” Molecular Therapy - Nucleic Acids 26 (2021): 174–191.

MLA   Click to copy
Cerro-Herreros, E., et al. “Preclinical Characterization of AntagomiR-218 as a Potential Treatment for Myotonic Dystrophy.” Molecular Therapy - Nucleic Acids, vol. 26, 2021, pp. 174–91, doi:10.1016/j.omtn.2021.07.017.

@article{cerro-herreros2021a,
  title = {Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy},
  year = {2021},
  journal = {Molecular Therapy - Nucleic Acids},
  pages = {174-191},
  volume = {26},
  doi = {10.1016/j.omtn.2021.07.017},
  author = {Cerro-Herreros, E. and González-Martínez, I. and Moreno, N. and Espinosa-Espinosa, J. and Fernández-Costa, J.M. and Colom-Rodrigo, A. and Overby, S.J. and Seoane-Miraz, D. and Poyatos-García, J. and Vilchez, J.J. and López de Munain, A. and Varela, M.A. and Wood, M.J. and Pérez-Alonso, M. and Llamusí, B. and Artero, R.}
}